Bone Resorption, Osteoclastogenesis and Adalimumab

Sponsor
Université de Sherbrooke
Study ID
NCT02035800
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Adalimumab — DRUG
    Patient will received medication as standard of care

Study Details

Broca II is the prolongation of the original study name BROCA. In BROCA study, only 25 patients participated and it was not enough to concluded clearly our hypothesis.

Key Dates

Start date
May 31, 2013
Status verified
May 2018
Primary completion
Dec 31, 2018
Completion
Dec 31, 2019

Study Design

Enrollment
120 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Adalimumab (humira)
    As standard of care.

Primary Outcome Measure

Verify if the treatment with Adalimumab may be associated with a reduction in the number of osteoclasts. [ Time Frame: 6 months after treatment ]

Central Contacts

Related Studies